News
-
-
-
-
-
-
PRESS RELEASE
Laxxon Medical Announces Development Program for Non-Invasive, 3D Printed Oral GLP-1 Asset, Offering an Alternative to GLP-1 Injections on Market
Laxxon Medical announces development program for LXM.2, a 3D printed oral GLP-1 receptor agonist for obesity treatment, offering an alternative to injections. Utilizes SPID® platform technology for enhanced bioavailability -
-
-
-